iBio, Inc. (NYSE AMEX:IBIO)
, a leader in new transient expression technologies for the development and production of biologics using plants, today announced that it has been added to the Russell Microcap Index, according to the definitive list of additions posted June 27 at:
Membership in the Russell Microcap Index, which remains in place for at least one year, means automatic inclusion in the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective market capitalization rankings and style attributes. “We are pleased to have another objective confirmation of our progress, and additional exposure to a wider audience of institutional investors,” said Robert B. Kay, iBio’s Executive Chairman and Chief Executive Officer.
Russell Indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. An industry-leading $3.9 trillion in institutional assets are currently benchmarked to Russell Indexes.
About iBio, Inc.
iBio develops and offers product applications of its iBioLaunch™ platform, offering collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. Advantages over other systems include: success with proteins difficult or impossible to produce with other methods; broadly applicable to biologics, including monoclonal antibodies, other therapeutic proteins and vaccines; enables rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more. Additional benefits include a practically unlimited surge capacity for remedial action against bioterrorism and pandemic disease; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production. Further information is available at:
Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such
involve a number of risks and uncertainties such as competitive factors,
development, market demand, and the Company's ability to obtain new contracts and
estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.